The mechanism involved were further investigated by examining associated changes in the HSP pathway and comparing with those produced by metformin, an anti-diabetic drug which has been suggested to have benefits for NASH (Clarke et al., 2015). Here, HSP90B2P is linked to metabolic dysfunction-associated steatohepatitis.